Printer Friendly

NOVEL ANTI-CANCER DRUG LICENSED TO ALPHA THERAPEUTIC

 NOVEL ANTI-CANCER DRUG LICENSED TO ALPHA THERAPEUTIC
 LOS ANGELES, Nov. 11 /PRNewswire/ -- Alpha Therapeutic Corporation


announced today the signing of a licensing agreement with Techniclone International (OTC: TCLN) for the development and commercialization of the LYM-1 monoclonal antibody, a novel anti-cancer agent. The agreement is for marketing in the United States, Canada, Mexico, Central America, South America, Asia, and the European countries of the United Kingdom, Spain, Italy, and Germany.
 LYM-1 was developed by Dr. Alan Epstein, associate professor at the University of Southern California Medical Center. To date, it has been administered in a radiolabeled intravenous form to over 50 relapsed Non- Hodgkin's Lymphoma patients by Dr. Gerald DeNardo of the University of California at Davis.
 In 1992, according to Cancer Facts & Figures, there will be 41,000 new cases of Non-Hodgkin's Lymphoma, with an estimated 19,000 deaths. Relapsed Non-Hodgkin's Lymphoma is currently treated with multi-agent chemotherapy regimens. Based on his clinical experience with radiolabeled LYM-1, Dr. DeNardo said, "I am encouraged by the responses and relatively mild toxicity observed to date in patients with advanced disease."
 According to Jack Whalen, M.D., general manager, Pharmaceutical Division, Alpha Therapeutic, "Under the terms of this agreement, Alpha Therapeutic is responsible for conducting all remaining development work necessary for regulatory approval and for all commercial activities."
 Techniclone International will be responsible for the manufacturing and distribution of radiolabled LYM-1. A 12,000-square-foot GMP manufacturing facility in Tustin, Calif., is scheduled for completion by the end of 1992. As part of this agreement, Alpha Therapeutic has a six-month option period for Techniclone International's other research product opportunities including Tumor Necrosis Targeting (TNT) technology, cell permeation enhancement technology and other monoclonal antibody research.
 "LYM-1 could be an important contribution as an additional agent for the treatment of Non-Hodgkin's Lymphoma," said Dr. Whalen. "Because of LYM-1's specificity for B-Cells, LYM-1 is anticipated to provide preferential delivery of radiotherapy to lymphoma cells. Alpha Therapeutic plans to initiate further development work as soon as possible," he added.
 -0- 11/11/92
 /NOTE TO EDITORS: The following references are available from Alpha:
 -- Gobuty A, DeNardo G, DeNardo S. "LYM-1 Radioimmunotherapy: A Case History of How We Do It." Antibody, Immunoconjugates, and Radiopharmaceuticals. 5:1, 1992.
 -- DeNardo G, DeNardo S, O'Grady L, Levy N, Adams G, and Mills S. "Fractioned Radioimmunotherapy of B-Cell Malignancies with 13II-LYM-1." Cancer Research. (Supp)50, 1990.
 -- Epstein A, Marder R, Winter J, Stathopoulos E, Chin F, Parker J, and Taylor C. "Two New Monoclonal Antibodies, LYM-1 and LYM-2, Reactive with Human B-Lymphocytes and Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential." Cancer Research. 47, 1987/
 /CONTACT: Jack Whalen, M.D., general manager, 213-227-7499, or Sandy Bryant, Ph.D., senior clinical project manager, 213-227-7633, both of Alpha Therapeutic; or Lon H. Stone, CEO of Techniclone International, 714-838-0500/
 (TCLN) CO: Alpha Therapeutic Corporation; Techniclone International ST: California IN: MTC SU: LIC


GK-AH -- NY045 -- 9766 11/11/92 13:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1992
Words:485
Previous Article:PAINEWEBBER INCORPORATED ADDS RAYCHEM TO ITS FOCUS LIST
Next Article:AMERICA'S MANUFACTURING BASE IS KEY TO AMERICA'S FUTURE GROWTH
Topics:


Related Articles
BIOMIRA ANNOUNCES EXCLUSIVE WORLD RIGHTS TO PEPTIDE ANTIGEN COULD LEAD TO 'DESIGNER DRUGS' AGAINST COMMON CANCERS
VERTEX AND ALPHA THERAPEUTIC CORPORATION ENTER DEVELOPMENT AGREEMENT FOR SICKLE CELL ANEMIA COMPOUND
ISIS PHARMACEUTICALS INITIATES CLINICAL TRIALS WITH NOVEL ANTISENSE CANCER COMPOUND TARGETED TO PKC-ALPHA INHIBITION
MAXIM PHARMACEUTICALS COMPLETES $3,275,000 PRIVATE PLACEMENT FINANCING
Sheffield Medical's Ion Pharmaceuticals Exercises License Option For Sickle Cell Anemia Therapy; Renews Sponsored Research Agreement
Vertex Pharmaceuticals and Alpha Therapeutic Corporation Terminate Hemoglobin Program Collaboration
Cytokine Networks and IDEC Pharmaceuticals Sign Licensing and Development Agreement
SK Corporation Announces CNS Licensing Agreement with Janssen Research Foundation.
Viragen licenses Oxford BioMedica's LentiVector gene delivery system for use in Avian Transgenics biomanufacturing program.
Prolexys licenses anti-cancer compounds.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters